Under assault by Carl Icahn and facing stiff regulatory oversight following some embarrassing manufacturing blunders, Genzyme is getting back to basics. In a series of strategic moves, the biotech company says it will buy back $2 billion worth of its stock as it considers how to rid itself of three businesses that are not part of its core operation. Report